Inhibikase Therapeutics (IKT) EV/FCF: History & Chart

Inhibikase Therapeutics, Inc.(IKT)

Biotechnology · Wilmington, DE

$1.97-0.03 (-1.75%)

Delayed quote: Oct 6, 2026, 10:20 AM EDT

About Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.

Wilmington, DE

35 employees

www.inhibikase.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Mark T. Iwicki

View full financials

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Inhibikase Therapeutics, Inc. (IKT)	$259.44M	N/A	N/A	N/A	N/A
EyePoint Pharmaceuticals, Inc. (EYPT)vs ›	$257.81M	N/A	48.59x	48.59x	48.59x
AC Immune S.A. (ACIU)vs ›	$257.64M	N/A	4.58x	4.76x	4.76x
Eupraxia Pharmaceuticals Inc. (EPRX)vs ›	$262.48M	N/A	N/A	N/A	N/A
Anika Therapeutics, Inc. (ANIK)vs ›	$255.75M	428.21x	210.95x	227.91x	182.13x
Century Therapeutics, Inc. (IPSC)vs ›	$255.32M	N/A	N/A	N/A	N/A
Lexeo Therapeutics, Inc. Common Stock (LXEO)vs ›	$250.09M	N/A	N/A	N/A	N/A
Indaptus Therapeutics, Inc. (INDP)vs ›	$271.78M	N/A	1.69x	1.69x	1.69x
Aurora Cannabis Inc. (ACB)vs ›	$273.16M	N/A	N/A	N/A	N/A
Fate Therapeutics, Inc. (FATE)vs ›	$273.33M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EV/FCF RATIO

TTM

Inhibikase Therapeutics, Inc. (IKT)

$259.44M

N/A

EyePoint Pharmaceuticals, Inc. (EYPT)vs ›

$257.81M

N/A

48.59x

AC Immune S.A. (ACIU)vs ›